Hahn Mark W's Form 4 filing
Verona Pharma plc (VRNA) · filed Feb 3, 2022
- Accession no.
- 0001104659-22-011438
- Filed
- Feb 3, 2022
- Trade date
- Feb 1-2, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 3 non-derivative transactions. Open-market sales total $7.92K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Hahn Mark WCIK 0001408502 | Officer (Chief Financial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 1, 2022 | Ordinary Shares | AGrant or awardAcquired | +133,776 | $0.75F2 | +$100,332 | 16,124,896 | Direct | |
| Feb 1, 2022 | Ordinary Shares | FTax withholdingDisposed | −288,320 | $0.78F4 | −$224,889.6 | 15,836,576 | Direct | |
| Feb 2, 2022 | Ordinary Shares | SSaleDisposed | −10,416 | $0.76F6 | −$7,916.16 | 15,826,160 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported represents the closing price of the Issuer's ADSs on the Nasdaq Stock Market LLC on January 28, 2022 divided by eight (8).
Referenced by the price of 1 transaction in Table I.
- F4
The price reported represents the closing price of the Issuer's ADSs on the Nasdaq Stock Market LLC on January 31, 2022 divided by eight (8).
Referenced by the price of 1 transaction in Table I.
- F6
The price reported is a weighted average price, and is based on the sale price of the ADSs divided by eight (8). The securities were sold in multiple transactions at per share prices ranging from $0.7462 to $0.7863. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote 5.
Referenced by the price of 1 transaction in Table I.